Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.

Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases, has been navigating a complex landscape of ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Neurocrine Biosciences begins phase 3 registrational study of osavampator as an adjunctive therapy to treat major depressive disorder: San Diego Wednesday, January 29, 2025, 18:00 ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on NBIX stock, giving a Hold rating on January 21.Invest with Confidence: ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive ...